Search

Your search keyword '"Wan, Fangning"' showing total 155 results
Start Over Author "Wan, Fangning"
155 results on '"Wan, Fangning"'

8. Supplementary Data from A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration

Author

Wang, Beihe, primary, Liu, Chang, primary, Wei, Yu, primary, Meng, Jin, primary, Zhang, Yingjian, primary, Gan, Hualei, primary, Xu, Xiaoping, primary, Wan, Fangning, primary, Pan, Jian, primary, Ma, Xuejun, primary, Hu, Silong, primary, Freedland, Stephen J., primary, Song, Shaoli, primary, Ye, DingWei, primary, and Zhu, Yao, primary

Published
2023
Full Text
View/download PDF

10. Application of Internet-based multidisciplinary management in patients with genitourinary cancers in China: A brief introduction to a new model of healthcare service for cancer survivors during COVID-19 pandemic

Author

Zhu, Yu, primary, Jin, Shengming, additional, Fu, Hangcheng, additional, Zhang, Hailiang, additional, Lu, Xiaolin, additional, Gu, Chengyuan, additional, Gu, Weijie, additional, Wan, Fangning, additional, Yang, Weiyi, additional, Qin, Xiaojian, additional, and Ye, Dingwei, additional

Published
2022
Full Text
View/download PDF

14. Inherited Mutations in Chinese Men With Prostate Cancer

Author

Zhu, Yao, primary, Wei, Yu, additional, Zeng, Hao, additional, Li, Yonghong, additional, Ng, Chi-Fai, additional, Zhou, Fangjian, additional, He, Caiyun, additional, Sun, Guangxi, additional, Ni, Yuchao, additional, Chiu, Peter K.F., additional, Teoh, Jeremy Y.C., additional, Wang, Beihe, additional, Pan, Jian, additional, Wan, Fangning, additional, Dai, Bo, additional, Qin, Xiaojian, additional, Lin, Guowen, additional, Gan, Hualei, additional, Wu, Junlong, additional, and Ye, Dingwei, additional

Published
2022
Full Text
View/download PDF

21. m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma

Author

Xu, Wenhao, primary, Tian, Xi, additional, Liu, Wangrui, additional, Anwaier, Aihetaimujiang, additional, Su, Jiaqi, additional, Zhu, Wenkai, additional, Wan, Fangning, additional, Shi, Guohai, additional, Wei, Gaomeng, additional, Qu, Yuanyuan, additional, Zhang, Hailiang, additional, and Ye, Dingwei, additional

Published
2021
Full Text
View/download PDF

22. Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma

Author

Xu, Wenhao, primary, Hu, Xiaoxin, additional, Anwaier, Aihetaimujiang, additional, Wang, Jun, additional, Liu, Wangrui, additional, Tian, Xi, additional, Zhu, Wenkai, additional, Ma, Chunguang, additional, Wan, Fangning, additional, Shi, Guohai, additional, Qu, Yuan-Yuan, additional, Zhang, Hailiang, additional, and Ye, Dingwei, additional

Published
2021
Full Text
View/download PDF

23. Identification of a methylation panel aid in risk stratification in node‐positive penile squamous cell carcinoma

Author

Gu, Weijie, primary, Wan, Fangning, additional, Chen, Jun, additional, Gan, Hualei, additional, Wang, Beihe, additional, Wei, Yu, additional, Zhang, Guiming, additional, Zhou, Jiaquan, additional, Ding, Xuefei, additional, Zhang, Peipei, additional, Jin, Shengming, additional, Xu, Qinghua, additional, Ye, Dingwei, additional, and Zhu, Yao, additional

Published
2020
Full Text
View/download PDF

24. A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration

Author

Wang, Beihe, primary, Liu, Chang, additional, Wei, Yu, additional, Meng, Jin, additional, Zhang, Yingjian, additional, Gan, Hualei, additional, Xu, Xiaoping, additional, Wan, Fangning, additional, Pan, Jian, additional, Ma, Xuejun, additional, Hu, Silong, additional, Freedland, Stephen J., additional, Song, Shaoli, additional, Ye, DingWei, additional, and Zhu, Yao, additional

Published
2020
Full Text
View/download PDF

25. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers

Author

Wang, Jun, primary, Xu, Wenhao, additional, Wang, Beihe, additional, Lin, Guowen, additional, Wei, Yu, additional, Abudurexiti, Mierxiati, additional, Zhu, Wenkai, additional, Liu, Chang, additional, Qin, Xiaojian, additional, Dai, Bo, additional, Wan, Fangning, additional, Zhang, Hailiang, additional, Zhu, Yao, additional, and Ye, Dingwei, additional

Published
2020
Full Text
View/download PDF

26. Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer

Author

Abudurexiti, Mierxiati, primary, Zhu, Wenkai, additional, Wang, Yuchen, additional, Wang, Jun, additional, Xu, Wenhao, additional, Huang, Yongqiang, additional, Zhu, Yao, additional, Shi, Guohai, additional, Zhang, Hailiang, additional, Zhu, Yiping, additional, Shen, Yijun, additional, Dai, Bo, additional, Wan, Fangning, additional, Lin, Guowen, additional, and Ye, Dingwei, additional

Published
2020
Full Text
View/download PDF

27. Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status

Author

Wang, Beihe, primary, Gu, Weijie, additional, Wan, Fangning, additional, Wei, Yu, additional, Xiao, Wenjun, additional, Lu, Xiaolin, additional, Zhang, Guiming, additional, Zhou, Jiaquan, additional, Wang, Qifeng, additional, Ding, Xuefei, additional, Azizi, Mounsif, additional, Spiess, Philippe E., additional, Ye, DingWei, additional, and Zhu, Yao, additional

Published
2020
Full Text
View/download PDF

29. Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data

Author

Tian, Xi, primary, Xu, Wenhao, additional, Wang, Yuchen, additional, Anwaier, Aihetaimujiang, additional, Wang, Hongkai, additional, Wan, Fangning, additional, Zhu, Yu, additional, Cao, Dalong, additional, Shi, Guohai, additional, Zhu, Yiping, additional, Qu, Yuanyuan, additional, Zhang, Hailiang, additional, and Ye, Dingwei, additional

Published
2020
Full Text
View/download PDF

30. Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma

Author

Ding-wei Ye, Shi Guohai, Chun-guang Ma, Zhang Hailiang, Dai Bo, Wan Fangning, Shen Yi-jun, Zhu Yao, and Zhu Yi-ping

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, soluble carriers, clear cell renal cell carcinoma, Bioinformatics, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, Gene expression, medicine, transporters, Gene, Kidney, business.industry, Sunitinib, Hazard ratio, medicine.disease, Clear cell renal cell carcinoma, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cohort, biomarker, prognosis, business, medicine.drug, Research Paper
Abstract

The soluble carrier (SLC) family plays an important role in cell metabolism. The purpose of the current study was to screen SLCs as potential prognostic factors in clear cell renal cell carcinoma (ccRCC). A total of 509 patients with ccRCC from The Cancer Genome Atlas (TCGA) cohort were enrolled in this study. The expression profile of SLCs was obtained from the TCGA RNAseq database. Metadata of the TCGA cohort, including age, sex, TNM stage, tumor grade, American Joint Committee on Cancer stage, laterality, and overall survival, were collected. Univariate and multivariate Cox proportional hazards regression models were used to analyze the relative factors. Prognosis-associated genes were further validated in a Fudan University Shanghai Cancer Center (FUSCC) cohort consisting of 178 patients. Among a total of 364 SLC transporters, 61 were independent predictors of ccRCC patient overall survival. Among the 61 SLC transporters, 26 were significantly downregulated and 23 were significantly upregulated in tumor tissues compared with non-malignant kidney tissues. Analyses of two open source, RNA expression data sets on sunitinib response revealed that SLC10A2 was downregulated in tyrosine kinase inhibitor-resistant samples. We validated SLC10A2 expression in the FUSCC cohort and showed that SLC10A2 expression was an independent prognostic predictor of overall survival of ccRCC (hazard ratio=0.432, 95% CI: 0.204-0.915). Our results identified a number of associations of SLC gene expression with prognosis of ccRCC patients, indicating that these genes may represent possible oncogenes that could serve as therapeutic targets of ccRCC.

Published
2017

31. m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma.

Author

Xu, Wenhao, Tian, Xi, Liu, Wangrui, Anwaier, Aihetaimujiang, Su, Jiaqi, Zhu, Wenkai, Wan, Fangning, Shi, Guohai, Wei, Gaomeng, Qu, Yuanyuan, Zhang, Hailiang, and Ye, Dingwei

Subjects
RENAL cell carcinoma, IMMUNE checkpoint proteins, TUMOR microenvironment, REGULATORY T cells, RNA methylation, METHYLATION
Abstract

Background: This study aims to establish an N6-methyladenosine (m6A) RNA methylation regulators-mediated methylation model and explore its role in predicting prognostic accuracy of immune contexture and characterizations of clear cell renal cell carcinoma (ccRCC). Methods: The m6A modification subclasses (m6AMS) were identified by unsupervised cluster analysis and three clusters were determined by consensus clustering algorithm in a discovering cohort. Testing and real-world validation cohorts were used to identify predictive responses for immune checkpoint therapies (ICTs) of m6AMS. Results: Prognostic implications landscape of m6A regulators in cancers and its differential expression levels in ccRCC patients were identified. Based on discovering cohort, ccRCC were automatically divided into three m6AMS, and cluster 3 showed significant worse survival than cluster 1/2. Importantly, it was found that the immune checkpoint molecules expression was significantly elevated in cluster 3. Besides, m6A scoreLow group (cluster 1&2) have significantly elevated TIDE score compared with m6A scoreHigh group (cluster 3). There was conspicuous tertiary lymphoid tissue, aggressive phenotype, elevated glycolysis, expression of PD-L1, abundance of CD8+ T cells, CD4+ FOXP3+ Treg cells and TCRn immune cells infiltration in the high m6A score group. Interestingly, there are significantly increased patients with clinical benefit in m6A scoreHigh group in 368 patients receiving ICTs from testing IMvigor210 (n = 292) and validation FUSCC (n = 55) cohorts. Conclusion: Our discovery highlights the relationship between tumor epigenetic heterogeneity and immune contexture. Immune-rejection cluster 3 has pro-tumorigenic immune infiltration, and shows significant clinical benefits for ccRCC patients receiving ICTs, enabling patient selection for future clinical treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness

Author

Wang, Xinbo, primary, Jin, Jiali, additional, Wan, Fangning, additional, Zhao, Linlin, additional, Chu, Hongshang, additional, Chen, Cong, additional, Liao, Guanghong, additional, Liu, Jian, additional, Yu, Yue, additional, Teng, Hongqi, additional, Fang, Lan, additional, Jiang, Cong, additional, Pan, Weijuan, additional, Xie, Xin, additional, Li, Jia, additional, Lu, Xiaolin, additional, Jiang, Xuejun, additional, Ge, Xin, additional, Ye, Dingwei, additional, and Wang, Ping, additional

Published
2019
Full Text
View/download PDF

41. Identification of a methylation panel aid in risk stratification in node‐positive penile squamous cell carcinoma.

Author

Gu, Weijie, Wan, Fangning, Chen, Jun, Gan, Hualei, Wang, Beihe, Wei, Yu, Zhang, Guiming, Zhou, Jiaquan, Ding, Xuefei, Zhang, Peipei, Jin, Shengming, Xu, Qinghua, Ye, Dingwei, and Zhu, Yao

Subjects
LYMPHADENECTOMY, PENILE cancer, SQUAMOUS cell carcinoma, METHYLATION, PROGNOSIS, SURVIVAL analysis (Biometry), MULTIVARIATE analysis
Abstract

Molecular prognostic factors for individualized treatment of squamous cell carcinoma (SCC) are poorly defined. Our study developed and validated a novel molecular tools aid in preinguinal and postinguinal lymphadenectomy risk stratification in node‐positive penile SCC. Patients with node‐positive penile SCC who underwent inguinal or ilioinguinal lymphadenectomy were divided into three cohorts: a discovery set, a development set and a validation set. The local ethics committee approved the study. The primary endpoint was cancer‐specific survival (CSS). At the discovery stage, 17 CpG sites were significantly associated with CSS. In the development set, we constructed a 3‐CpG‐based prognostic score for survival prediction. The hazard ratio (HR) of the panel (dichotomized using the optimal cutoff) was 5.8 in the multivariate analyses (P <.001). The addition of the methylation score significantly improved the pN‐stage C‐index from 0.70 to 0.79 (incremental C = 0.09, P <.001). In the validation set, the methylation panel showed a HR of 9.9 in the multivariate analyses. The addition of the molecular marker improved the pN‐stage C‐index from 0.69 to 0.78 (incremental C = 0.09, P <.001). The methylation score remarkably separated survival curves in different pN stages, which indicate that the tool can be applied to tailor the treatment in both preinguinal and postinguinal lymphadenectomy settings. We developed and validated a prognostic methylation panel for node‐positive penile SCC. The tool may aid in the risk stratification of the population with heterogeneous outcomes and needs prospective validation. Patients in high‐risk group may benefit from more aggressive therapy or clinical trials. What's new? Patients with node‐positive penile cancer are not a homogeneous group, and new prognostic markers other than the pN stage are urgently needed. Here, the authors developed and validated a methylation score to predict survival outcome in node‐positive penile cancer. In pre‐inguinal lymphadenectomy patients, the risk score provides objective information supporting the decision‐making process for neoadjuvant therapy. In post‐inguinal lymphadenectomy patients, the risk score in conjunction with the pN stage can help tailor the multimodality treatment. The risk score can be easily measured from primary penis tumor samples and objectively evaluates the survival outcomes of patients, with an accuracy above 70%. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results